Ascendis Pharma A (ASND) Operating Expenses (2013 - 2026)

Ascendis Pharma A has reported Operating Expenses for 13 years, with the latest figure at -$239.2 million in Q1 2026.

• Quarterly Operating Expenses fell 21.16% year-over-year to -$239.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$357.2 million (down 65.46% YoY) and the FY2025 annual result came in at -$110.6 million, down 256.82% from the prior year.
• Operating Expenses declined to -$239.2 million in Q1 2026 per ASND's latest filing, from -$110.6 million in the prior quarter.
• Over five years, Operating Expenses peaked at $203.2 million in Q2 2025 and troughed at -$239.2 million in Q1 2026.
• A 5-year average of $26.3 million and a median of $146.6 million in 2022 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses jumped 48.9% in 2024, then slumped 256.82% in 2025.
• Over 5 years, Operating Expenses stood at -$97.4 million in 2022, then surged by 37.74% to -$60.6 million in 2023, then surged by 48.9% to -$31.0 million in 2024, then plunged by 256.82% to -$110.6 million in 2025, then plunged by 116.27% to -$239.2 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered -$239.2 million, -$110.6 million, and -$210.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.